𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial

✍ Scribed by J.B. Deakin; S. Rahman; P.J. Nestor; J.R. Hodges; B.J. Sahakian

Book ID
105880651
Publisher
Springer
Year
2004
Tongue
English
Weight
210 KB
Volume
172
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interferon-Ξ± does not improve outcome at
Interferon-Ξ± does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial
✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 161 KB πŸ‘ 1 views

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal

Spironolactone Does Not Prevent Acute Mo
Spironolactone Does Not Prevent Acute Mountain Sickness: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group)
✍ Buddha Basnyat; Peter S. Holck; Matiram Pun; Stephen Halverson; Piotr Szawarski; πŸ“‚ Article πŸ“… 2011 πŸ› Elsevier Science 🌐 English βš– 564 KB

## Objectives: Over the last 20 years a number of small trials have reported that spironolactone effectively prevents acute mountain sickness (ams), but to date there have been no large randomized trials investigating the efficacy of spironolactone in prevention of ams. hence, a prospective, double